MARKET

PCSA

PCSA

Processa Pharmaceuticals Inc
NASDAQ
2.160
+0.100
+4.85%
After Hours: 2.074 -0.086 -3.98% 16:26 09/08 EDT
OPEN
2.150
PREV CLOSE
2.060
HIGH
2.165
LOW
2.050
VOLUME
35.84K
TURNOVER
--
52 WEEK HIGH
14.24
52 WEEK LOW
1.670
MARKET CAP
6.03M
P/E (TTM)
-0.3743
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PCSA last week (0831-0904)?
Weekly Report · 1d ago
Weekly Report: what happened at PCSA last week (0824-0828)?
Weekly Report · 08/31 09:47
Weekly Report: what happened at PCSA last week (0817-0821)?
Weekly Report · 08/24 09:47
Weekly Report: what happened at PCSA last week (0810-0814)?
Weekly Report · 08/17 09:48
Based on the provided financial report articles, I generated the title for the article: **"Quarterly Financial Report for Q2 2026: [Company Name]"** Please note that the title may not be exact, as the provided text does not contain the company name.
Press release · 08/14 21:20
Weekly Report: what happened at PCSA last week (0803-0807)?
Weekly Report · 08/10 09:45
Processa Pharmaceuticals Shareholders Approve Key Governance Changes
TipRanks · 08/04 21:45
Weekly Report: what happened at PCSA last week (0727-0731)?
Weekly Report · 08/03 09:44
More
About PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.

Webull offers Processa Pharmaceuticals Inc stock information, including NASDAQ: PCSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCSA stock methods without spending real money on the virtual paper trading platform.